Just noticed Abbott Labs (ABT) took a hit after their Q4 earnings, down 16% over the trailing 12 months. On the surface, looks rough - sales only grew 4.4% to $11.5B, and guidance for 2026 wasn't inspiring either. Two segments stumbled: nutrition and diagnostics both underperformed.

But here's what caught my attention: the core medical device business is actually humming along nicely with 12.3% growth. Their diabetes care unit jumped 14.5% year-over-year, driven by the FreeStyle Libre franchise. They've been smart about expanding beyond insulin-dependent patients - the Libre Rio targets type 2 patients not on insulin, and Lingo goes after non-diabetics interested in glucose monitoring. The addressable market is way bigger than people realize.

Structural heart devices like MitraClip and TriClip are still solid performers. And then there's the Exact Sciences acquisition for $21B - that's a game-changer for their diagnostics division. Exact Sciences brings Cologuard (leading non-invasive colorectal cancer test) and new early-detection cancer diagnostics to the table. Cancer diagnostics is growing fast, and having Abbott's resources behind these products should unlock real potential.

Now, what actually matters for income investors: Abbott is a legitimate Dividend King with 54 straight years of dividend increases. That's not something you see every day. At around $106 per share, you can actually build a meaningful dividend position with just $150. The Dividend King status alone tells you this company takes shareholder returns seriously through thick and thin.

Yeah, the earnings miss stung, but the underlying growth drivers are solid. Medical devices performing well, major acquisition adding scale, and that dividend track record speaks volumes. For anyone looking at dividend stocks, Abbott deserves serious consideration despite the recent noise.